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Emerging evidence from both basic and clinical research demonstrates an important role for
endocannabinoid (ECB) signaling in the processing of emotionally salient information, learn-
ing, and memory. Cannabinoid transmission within neural circuits involved in emotional
processing has been shown to modulate the acquisition, recall, and extinction of emo-
tionally salient memories and importantly, can strongly modulate the emotional salience
of incoming sensory information. Two neural regions in particular, the medial prefrontal
cortex (PFC) and the basolateral nucleus of the amygdala (BLA), play important roles in
emotional regulation and contain high levels of cannabinoid receptors. Furthermore, both
regions show profound abnormalities in neuropsychiatric disorders such as addiction and
schizophrenia. Considerable evidence has demonstrated that cannabinoid transmission
functionally interacts with dopamine (DA), a neurotransmitter system that is of exceptional
importance for both addictive behaviors and the neuropsychopathology of disorders like
schizophrenia. Research in our laboratory has focused on how cannabinoid transmission
both within and extrinsic to the mesolimbic DA system, including the BLA→mPFC cir-
cuitry, can modulate both rewarding and aversive emotional information. In this review, we
will summarize clinical and basic neuroscience research demonstrating the importance of
cannabinoid signaling within this neural circuitry. In particular, evidence will be reviewed
emphasizing the importance of cannabinoid signaling within the BLA→mPFC circuitry
in the context of emotional salience processing, memory formation and memory-related
plasticity. We propose that aberrant states of hyper or hypoactive ECB signaling within
the amygdala-prefrontal cortical circuit may lead to dysregulation of mesocorticolimbic DA
transmission controlling the processing of emotionally salient information. These distur-
bances may in turn lead to emotional processing, learning, and memory abnormalities
related to various neuropsychiatric disorders, including addiction and schizophrenia-related
psychoses.
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FUNCTIONAL ROLES FOR CANNABINOID SIGNALING IN
NEURAL EMOTIONAL PROCESSING CENTERS
The endocannabinoid (ECB) system is widely distributed in the
mammalian brain and demonstrates relatively high density in
neural regions implicated in the processing of emotionally salient
information, such as the basolateral nucleus of the amygdala
(BLA), prefrontal cortex (PFC), VTA, and NAc (1, 2). Natu-
rally occurring ECBs include 2-arachidonoylglycerol (2-AG) and
anandamide, which produce their actions via distinct neurophys-
iological mechanisms. Thus, while 2-AG is known to act as a
fast-acting and transient retrograde messenger, anandamide can
produce slower retrograde synaptic effects (3). In both cases, the
canonical understanding of ECB function is that ECBs are gener-
ally released from post-synaptic neuronal elements and feedback
in a retrograde manner onto pre-synaptic terminals, which may
be either excitatory or inhibitory in nature (4). Retrograde synap-
tic modulation via the ECB system is known to be involved in
short-term synaptic depression and can suppress both excita-
tory and inhibitory signaling within specific neuronal circuits
(3, 4). As will be described presently, given this anatomical and
pharmacological complexity, a wide variety of potential func-
tional consequences can be attributed to CB1 receptor activation
(via either ECBs, plant-derived or synthetic cannabinoid receptor
agents). For within the BLA, CB1 receptors are localized primar-
ily on inhibitory local GABAergic interneurons or terminals, but
are absent in the adjacent central nucleus (1, 5, 6). In this case,
activation of BLA CB1 receptors is known to decrease feedforward
inhibition via inhibitory interneurons thereby increasing the activ-
ity of BLA projection neurons (7), leading to modulatory effects in
efferent projection targets, such as the PFC (8, 9). Conversely, acti-
vation of CB1 receptors associated with excitatory pre-synaptic
elements, such as glutamatergic terminals, may be capable of
producing net inhibitory post-synaptic effects, depending upon
the specific neuronal circuit under investigation. In both cases,
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emerging evidence points to the primary functional role of ECB
signaling as indirectly modulating neuronal outputs via actions on
pre-synaptic elements, primarily involving the inhibition of feed-
forward inhibitory influences on these neuronal outputs. As will
be reviewed below, such mechanisms implicate the ECB system as
a critical functional relay capable of controlling the output of a
variety of neural emotional processing centers, including connec-
tions between the BLA and PFC, and the regulation of DAergic
signaling within the mesocorticolimbic circuit.
EVIDENCE FOR DYSREGULATED ENDOCANNABINOID
SIGNALING IN SCHIZOPHRENIA AND CO-MORBID
ADDICTIVE BEHAVIORS
Abnormal emotional processing, learning and memory are core
features of various neuropsychiatric conditions, including schizo-
phrenia and addiction. Disturbances in the ability to form appro-
priate associative memories and perform adaptive associative
learning tasks, has been identified as critical neuropsychopatho-
logical features in both schizophrenia (10, 11) and addiction
(12, 13). In both cases, patients may be more likely to inap-
propriately assign distorted emotional significance to internal
or external stimuli, leading to aberrant associative memory for-
mation. Drug-dependent individuals, including those presenting
substance abuse co-morbidly with other neuropsychiatric disor-
ders, attribute pathologically elevated motivational salience to
drug-predictive cues, leading to compulsive drug seeking and
relapse. Individuals with schizophrenia may attribute inappropri-
ate emotional salience (either appetitive or aversive) to events or
stimuli within the environment that healthy individuals would
dismiss as non-significant, ultimately leading to delusional beliefs
and/or psychotic ideation. In addition, substance abuse is highly
co-morbid with schizophrenia-related psychopathology (14). Sig-
naling through the brain’s ECB system is involved in a plethora
of behavioral, synaptic, and neuronal phenomena associated with
these processes, and is a critical modulator of both rewarding and
aversive emotionally salient information. However, emerging evi-
dence from both human and basic neuroscience research, points to
the importance of functional interactions between ECB signaling,
and sub-cortical transmission through the dopamine (DA) system,
as a nexus point to understanding how dysregulation of the ECB
system may relate to the well-established aberrations in DAergic
transmission,as a core neuropathological feature of both addiction
and schizophrenia. Indeed, mounting evidence implicates distur-
bances in neural reward pathways as underlying neuropathologi-
cal features of schizophrenia, indicated by abnormal blunting of
neural response patterns following exposure to normally reward-
ing stimuli (15–17). This evidence suggests a core underlying
disturbance in schizophrenia that transcends emotional valence,
comprising deficits in the processing of both rewarding, appetitive
information, along with aversive, negative emotional stimuli.
Considerable evidence from both human clinical and animal
modeling studies points to ECB-dependent mechanisms that may
be related to increased vulnerability to addictive behaviors and
schizophrenia-related psychopathology. Interestingly, these dis-
turbances have been associated both with genetic factors and
have also been demonstrated following acute or chronic expo-
sure to drugs that directly interact with the brains ECB systems,
most notably, cannabis. In terms of characterizing the dysregu-
lation of ECB signaling in schizophrenia-related symptomology,
a land-mark paper from Andréasson et al. (18) provided com-
pelling evidence suggesting that exposure to marijuana during
critical, adolescent windows of neurodevelopment was positively
correlated with an increased propensity to develop schizophrenia-
related psychoses in early adulthood. Examining a cohort of 45,570
Swedish military conscripts, this report described a significant
association between exposure levels to cannabis use in adoles-
cence and the later emergence of schizophrenia reported during a
15-year follow-up. The authors reported that the relative risk for
developing schizophrenia among heavy users of marijuana (>50
exposures) was 6.0 (95% confidence interval), compared with
non-users. Importantly, this association was reliable after control-
ling for the presence of other neuropsychiatric diseases and social
background, demonstrating that relative adolescent marijuana use
represented an independent risk factor for the later development of
schizophrenia. Andréasson et al. followed up this initial report with
a subsequent longitudinal study using a sub-group from the orig-
inal cohort (19). Comparing clinical records for schizophrenia-
diagnosed subjects reporting marijuana use on more than 10
occasions vs. subjects who had gone on to develop schizophrenia
in the absence of any reported marijuana exposure, still revealed a
relative risk factor for schizophrenia among the marijuana-using
sub-group as 4.1 (95% confidence interval). Causal roles for other
narcotic drug exposures in the marijuana-using sub-group were
ruled out. Intriguingly, the authors described a unique pattern of
psychopathology among the marijuana users, characterized with
a more acute onset of schizophrenia-related symptoms relative to
non-exposed control subjects.
In addition to longitudinal relationships between marijuana
exposure and the etiology of schizophrenia, considerable evidence
points to dysregulation of naturally occurring ECBs as correl-
ative factors linked to the occurrence of schizophrenia. Thus,
several reports have shown that cerebrospinal fluid (CSF) lev-
els of anandamide, a naturally occurring ECB, in medication-
naive patients with schizophrenia are significantly elevated and
negatively correlated with the presence of psychotic symptoms
(20–23). Analysis of post-mortem brain tissue samples from schiz-
ophrenia patients revealed that the levels 2-AG, were significantly
elevated relative to controls in several neural regions including
the cerebellum, hippocampus, and PFC (24). Further evidence
implicating a specific role for prefrontal cortical cannabinoid dys-
regulation as an etiological mechanism in schizophrenia has come
from post-mortem studies of schizophrenia brain samples. An
important study from Dalton et al. (25) analyzed cannabinoid
CB(1) receptor binding levels and mRNA expression in the dor-
solateral prefrontal cortex (DLPFC), comparing sub-populations
of paranoid or non-paranoid schizophrenia patients, relative to
healthy controls. Interestingly, this study reported a paranoid
schizophrenia-subtype specific effect with paranoid schizophre-
nia subjects displaying 22% higher levels of CB1 receptor binding
compared to controls or non-paranoid schizophrenia patients.
Similar results were reported by Jenko et al. (26), wherein CB1
receptor binding in the DLPFC was reported to be 20% higher in
schizophrenia relative to healthy control subjects. Similarly, Zavit-
sanou et al. (27) reported increased CB1 binding levels in samples
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of anterior cingulate cortex from schizophrenia patients. Such
findings strongly suggested that abnormalities in CB1 receptor sig-
naling within the PFC may relate specifically to paranoia-related
schizophrenia symptomology and more specifically, suggest that
a hyperactive state of CB1 activity within frontal cortical regions
may be linked to the emotional regulation disturbances found in
paranoid schizophrenia populations.
Beyond its well-established role in the processing of aversive
emotional information and memory encoding, considerable evi-
dence links the ECB system to the regulation of reward-related
processing, specifically in the context of the opiate-receptor sys-
tem. From a genetic perspective, genes encoding both the CB1
receptor (CNR1) and fatty acid amide hydrolase (FAAH) responsi-
ble for the breakdown of anandamide are located on chromosomes
6 and 1 in the 6q15 and 1p33 cytogenetic bands. Several reports
have suggested that polymorphic mutations in these genes may
be linked to addictive vulnerability to several drugs of abuse,
including alcohol (28), nicotine (29), cocaine (30), and heroin
(31). Cannabis use and exposure has long been theorized to rep-
resent a “gateway” drug, associated with an increased propensity
to use other drugs of abuse, either concomitantly, or following
long-term cannabis use. Such theories remain highly controversial
for a number of reasons. First, it is virtually impossible to con-
trol for strain variety of cannabis exposure, given that cannabis
strains may differ markedly in terms of relative THC or other
chemical constituents. Second, obtaining documented and reli-
able histories of cannabis exposure that rely on self-report are
difficult to acquire. Nevertheless, while such a “gateway” role for
cannabis exposure has not been causally demonstrated in human,
clinical populations, considerable evidence from basic neuro-
science research, demonstrates a causal role for CB1 signaling
in modulating sensitivity to the rewarding and/or dependence-
producing properties of other drug classes, particularly opiate-
class drugs, such as morphine and heroin, as will be discussed
presently.
Despite an abundance of clinical evidence linking disturbances
in prefrontal cortical cannabinoid signaling to schizophrenia
and addiction-related psychopathology, the precise mechanisms
related to these effects are not currently understood. However,
research from basic neuroscience studies using behavioral and
neuronal models of emotional processing and memory formation,
point to several important functional circuits and mechanisms,
which may underlie cortical CB1-mediated modulation of emo-
tional processing. Specifically, considerable evidence now suggests
important functional interactions between intra-cortical cannabi-
noid receptor substrates with sub-cortical DA transmission, and
via cross-talk with the BLA.
CANNABINOID MODULATION OF EMOTIONAL PROCESSING,
LEARNING, AND MEMORY IN THE AMYGDALA-PREFRONTAL
CORTICAL PATHWAY
Considerable evidence implicates the importance of functional
communication within the BLA→PFC pathway as a mediator
of emotionally salient learning, memory, and synaptic plasticity.
For example, acute exposure to stressful/aversive events triggers
long-term potentiation (LTP) or long-term depression within the
BLA→PFC circuit, respectively (32, 33). Single neurons within
the rodent mPFC show associative firing and bursting response
patterns during fear-related learning, through a BLA-dependent
input pathway (34). Similarly, neurons within the rodent BLA can
demonstrate associative neuronal responding to odor cues paired
with aversive stimuli such as foot-shock (35). In both cases, asso-
ciative neuronal responding to foot-shock-paired olfactory cues
can be demonstrated under full anesthesia, and are dependent
upon DA transmission (34–37). In terms of cannabinoid mod-
ulation of emotional learning and memory processing within
the BLA→PFC pathway, systemic administration of synthetic
agonists of CB1 receptors, such as WIN 55, 212-2, can potently
increase associative neuronal responding to fear-paired associative
cues, both by increasing neuronal firing frequency and by increas-
ing bursting activity of PFC neurons following presentations of
associative CS+ cues (38). In contrast, blockade of CB1 trans-
mission with CB1 receptor antagonists, were shown to completely
block the ability of PFC neurons to encode associative neuronal
responses to stimuli paired with foot-shock, demonstrating for the
first time, bi-directional modulation of fear memory acquisition
by activation or blockade of CB1 receptor transmission directly
in the PFC. These bi-directional neuronal associative effects could
be similarly demonstrated behaviorally; using an olfactory fear
conditioning assay in awake, behaving rats, direct intra-PFC CB1
receptor activation strongly potentiated fear memory formation
by increasing the emotional salience of normally non-salient fear
memories, using a sub-threshold foot-shock conditioning stimu-
lus. In contrast, blockade of intra-PFC CB1 transmission blocked
the formation of supra-threshold fear memory formation. Impor-
tantly, these effects were not related to any changes in sensory
or physiological, nociceptive sensitivity to the experience of the
foot-shock stimulation (38).
In the context of emotional memory formation, the PFC and
BLA represent a highly interconnected circuit, sharing functional
ascending and descending connections. Neurons within the BLA
are modulated by PFC inputs, with inputs from the PFC capable
of suppressing BLA output neuron activity and sensory evoked
excitation of BLA neurons, through DA-dependent mechanisms
(35, 37). In addition, as described previously, emotional experience
strongly modulates synaptic plasticity along the BLA→PFC cir-
cuit (32, 39). In terms of CB1 receptor modulation of the BLA
and PFC, both regions show wide distribution of CB1 recep-
tors, which have been demonstrated to modulate both the release
of glutamate from pre-synaptic terminals and γ-aminobutyric
acid (GABA) from local interneuron inhibitory elements (40–
43). Thus, cannabinoids acting within either region are capable
of modulating the activity of output neuronal populations and
exerting effects distally in target regions, including the mesolim-
bic DA pathway. For example, cannabinoid compounds strongly
modulate excitatory outputs from the PFC and BLA to neurons
within the NAc (7, 44). Systemic cannabinoid drug administration
also increases excitability of PFC neurons to VTA DAergic inputs
(45) and can indirectly increase VTA DA neuron excitability by
inhibiting GABAergic inhibition directly within the VTA (46).
CANNABINOID SIGNALING IN THE BLA>PFC PATHWAY:
MODULATORY EFFECTS ON EMOTIONAL PROCESSING AND
MEMORY
The amygdala is perhaps the most fully characterized neural region
involved in the processing of emotionally salient information,
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including both reward-related and aversive fear memories (34,
36, 47–49). High levels of CB1 receptors are localized in the BLA
region of the amygdala (2, 6) and CB1 transmission within the
BLA is involved in the regulation of associative learning and mem-
ory processing (50, 51). A wealth of evidence has demonstrated
that dysregulated emotional processing in patients with schizo-
phrenia is associated with abnormal activity patterns within the
amygdala. For example, distortions in the perception of emo-
tional valences associated with pictures of human faces showing
a range of emotion-related expressions is correlated with hyper-
active responses in the amygdala region of human schizophrenia
patients (52–54). Schizophrenia patient’s show markedly reduced
amygdala volumes (55) and these abnormalities are correlated
with specific stages of psychosis (56). Cannabinoids produce
both inhibitory and excitatory effects within BLA neuronal sub-
populations through both CB1 and non-CB1 receptor substrates
(7). Nevertheless, the precise mechanisms by which cannabinoids
may control neuronal output activity from the BLA is not entirely
clear.
Given the well-established relationships between the BLA and
PFC regions, we examined the effects of CB1 receptor modulation
directly within the BLA on the acquisition of fear memory and on
the modulation of distal neuronal activity in the prelimbic (PLC)
division of the rat PFC. Following bilateral activation or block-
ade of intra-BLA CB1 receptors, using WIN 55, 212-2, or AM-251,
respectively, we found that CB1 receptor activation within the BLA
could strongly amplify the salience and promote the formation
of associative olfactory fear memories to normally non-salient,
sub-conditioning threshold levels of foot-shock (9). In contrast,
blockade of CB1 transmission with a CB1 receptor antagonist
completely blocked the formation of associative fear memories
to normally supra-threshold levels of foot-shock. Concomitantly,
these same behaviorally effective doses of intra-BLA CB1 recep-
tor agonists or antagonists were able to bi-directionally control
the spontaneous neuronal activity patterns of sub-populations
of isolated neuronal units recorded in vivo, in the PLC; whereas
intra-BLA CB1 receptor activation caused a strong increase in a
plurality of recorded PLC neurons, blockade of CB1 receptors
caused a predominant decrease in these neuronal activity levels
(Figure 1). In addition to the effects induced by direct phar-
macological CB1 receptor blockade or activation, we found that
intra-BLA administration of AM 404, a synthetic anandamide
transport inhibitor and transient receptor potential cation chan-
nel subfamily V member 1 (TrpV1) receptor agonist, mimicked
the effects of direct CB1 receptor activation with WIN 55, 212-2,
suggesting that intra-BLA cannabinoid modulation of emotional
memory processing is dependent upon regulation of a tonic CB1
receptor-mediated pattern of activation. Together, such findings
are consistent with prior evidence demonstrating that (1) neurons
in the PFC involved in the encoding of associative fear memories
are comprised of a sub-population of cells that receive inputs from
the BLA (34) and (2) the ability of CB1 transmission within the
PFC to modulate emotional memory formation depends upon
functional inputs from the BLA (38). Further evidence also impli-
cates the importance of this pathway in cannabinoid-mediated
modulation of emotional memory formation. For example, Cam-
polongo et al. (57) reported that infusions of the CB1 agonist
WIN 55, 212-2 into the rodent BLA was able to enhance memory
retention during an inhibitory avoidance task, while blockade of
CB1 transmission produced the opposite effect. Interestingly, these
effects were dependent upon glucocorticoid transmission, suggest-
ing that intra-BLA modulation of emotional memory processing
interacts with stress-related signaling substrates. Such findings
are consistent with evidence demonstrating that attenuation of
ECB signaling within the BLA is involved in the activation of the
stress-response via the hypothalamic–pituitary–adrenal axis (58),
which further implicates the importance of intra-BLA CB1 trans-
mission as a critical regulatory component for the processing of
emotionally salient experiences.
CANNABINOID SIGNALING IN THE BLA→PFC PATHWAY:
INTEGRATIVE CONTROL OF EMOTIONAL PROCESSING AND
MEMORY-RELATED PLASTICITY
Considerable evidence links modulation of cannabinoid signaling
within the mammalian PFC as a critical modulator of emotional
processing and memory formation. Exposure to stressors has been
reported to increase expression levels of CB1 receptors directly
within the PFC (59) and, as noted previously, considerable evi-
dence, particularly from post-mortem analyses of brain tissue
from schizophrenia patients, has revealed pathological dysregu-
lation of CB1 receptor signaling in PFC regions. We have reported
that direct activation of CB1 receptor transmission in the rodent
PFC can potentiate the formation of associative fear memories
to cues paired with normally sub-threshold, non-salient levels of
foot-shock. Thus, associative responses to olfactory cues paired
with aversive foot-shock stimulation are strongly potentiated in
neuronal sub-populations recorded in the rat PFC (38). This CB1-
mediated potentiation in associative neuronal fear memory encod-
ing is reflected both in terms of increased associative bursting and
firing frequency rates. Importantly, the ability of intra-PFC CB1
receptor activation to potentiate emotional salience and memory
formation depends upon functional inputs from the BLA as PFC
neurons demonstrating potentiated emotional memory formation
represent a sub-population of PFC neurons that respond to dis-
crete, orthodromic electrical stimulation of the BLA. Furthermore,
reversible pharmacological inactivation of the BLA blocked the
emotional salience potentiating effects of intra-PFC CB1 receptor
activation (38).
Given the bi-directional effects of CB1 receptor modulation
within the BLA→PFC pathway in the neuronal and behav-
ioral processing of emotional memory, we further examined how
associative plasticity in the form of LTP within the BLA→PFC
pathway may be modulated by CB1 transmission. While previous
reports have demonstrated that intra-PFC CB1 signaling can mod-
ulate glutamatergic synaptic plasticity mechanisms (60), it was not
known how CB1 signaling may be involved in the mediation of
synaptic plasticity along the BLA→PFC pathway. After adapting
an in vivo electrophysiological protocol for inducing LTP within
the PFC following tetanic stimulation of the BLA first reported
by Maroun and Richter-Levin (39), we examined the effects of
pharmacological blockade of CB1 receptors on the induction of
BLA→PFC LTP (Figure 2A), via systemic administration of AM
251, prior to the induction of LTP in anesthetized rats (8). Consis-
tent with evidence implicating a functional relationship between
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FIGURE 1 | Intra-BLA CB1 receptor modulation controls the activity of
PLC neurons. (A) Microinfusions of the CB1 antagonist AM 251
(50–500 ng/0.5µl) strongly decreased the spontaneous firing frequency of a
plurality of recorded PLC neurons. (B) In contrast, microinfusions of the CB1
agonist WIN 55, 212-2 (50–500 ng/0.5µl) strongly increased the spontaneous
firing frequency of a plurality of recorded PLC neurons. (C) Summary of group
PLC neuronal data showing inhibitory effects on PFC neuronal activity
following intra-BLA infusions of AM 251. (D) Summary of group PFC neuronal
data showing excitatory effects on PLC neuronal activity following intra-BLA
infusions of WIN 55, 212-2. Adapted from Tan et al. (9).
CB1 transmission in the BLA→PFC pathway during associative
learning and memory processing, we found that CB1 receptor
blockade completely blocked the induction of LTP within the
BLA→PFC circuit (Figure 2B). Interestingly, this same systemic
dose of AM 251 was sufficient to completely block the formation
of associative fear memories in awake, behaving rats (Figure 2C).
Furthermore, functional disconnection experiments performed by
contralateral blockade of CB1 transmission in the BLA or PFC,
revealed that the acquisition of fear memory within this pathway
required simultaneous CB1 receptor activation in both regions.
Thus, the acquisition of associative fear memory within this cir-
cuit requires integrative CB1 receptor signaling, consistent with
the known functional interconnections between the BLA and PFC.
While this report was the first to demonstrate a functional role for
CB1 signaling in the development of LTP within the BLA→PFC
pathway, these findings are consistent with a large body of evidence
implicating the ECB system in the modulation of learning and
memory-related synaptic plasticity mechanisms in other neural
regions, particularly the hippocampus, wherein signaling through
CB1 receptor substrates is known to modulate associative synaptic
plasticity processes (61, 62). Thus, consistent with the known dis-
turbances in ECB signaling in PFC regions and the well-established
deficits in emotional processing within the amygdala-PFC circuit
in patients with schizophrenia (63), these findings demonstrate
that appropriate emotional processing and memory formation
within the BLA→PFC pathway requires integrative CB1 trans-
mission across this circuit. Hyper- or hypo-activation of CB1
receptor substrates within either region are sufficient to cause
pathological amplification of normally non-salient emotional
stimuli, or, a blunting of emotional salience toward environ-
mental stimuli that would normally produce adaptive associative
memories and learned behaviors (8, 38).
CANNABINOID CB1 RECEPTOR-MEDIATED MODULATION OF
REWARD PROCESSING: INTERACTIONS WITH OPIATE
REWARD SIGNALING
The brain’s naturally occurring opiate-receptor system and asso-
ciated neural circuitry represents an ideal experimental system to
examine how ECB transmission may modulate motivational states
and memory formation. Indeed, opiate-class stimuli, either phar-
macological formulations or naturally occurring opiate peptides,
serve as powerful reinforcers and conditioned stimuli during a
variety of reward-related learning and memory tasks in humans
and other animals. Considerable evidence using behavioral genetic
approaches has demonstrated several important functional inter-
relationships between ECB and opiate-related reward processing,
both in terms of opiate-related reward behaviors and in terms of
CB1 receptor-mediated modulation of neural regions critical for
opiate reward processing, such as the mesocorticolimbic system.
Early behavioral reports using genetic knock-out (KO) mutant
mice models of the CB1 receptor showed marked reductions
in heroin intravenous self-administration (64, 65). Interestingly,
the blunting of heroin self-administration in the CB1 KO mice
appeared to be specific to opiates (64). The mammalian VTA is a
critical neural substrate for the processing of the primary reward-
ing properties of opiates, through DA-dependent and non-DA
neuronal substrates (66, 67) and a large body of evidence has
demonstrated that cannabinoid compounds can acutely activate
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FIGURE 2 | Cannabinoid transmission controls synaptic plasticity and
fear memory formation in the BLA→PFC pathway. Effects of systemic
AM-251 pre-treatment on the induction of in vivo LTP along the BLA→PLC
pathway. (A) Using an in vivo LTP induction protocol in rats, we recorded
local field potentials in the PLC following the induction of LTP following
tetanic, electrical stimulation of the BLA. (B) Group data comparing
excitatory post-synaptic potential (EPSP) amplitudes from animals receiving
systemic injections of the CB1 receptor antagonist, AM 251 (1.0 mg/kg; i.p.)
vs. saline vehicle controls. AM 251 pre-treatment completely prevented the
induction of LTP along the BLA→PLC pathway. (C) Remarkably, this same
dose of systemic AM 251 (1.0 mg/kg; i.p.) completely blocked the
acquisition of fear memory in awake, behaving rats, as measured by
freezing behaviors following presentations of fear-associated olfactory
cues; **p<0.01; *p<0.05.
both the opiate and DAergic signaling systems. For example,
the acute administration of THC has been reported to increase
levels of β-endorphins and enkephalinergic peptides directly in
the mesolimbic DA pathway, including the VTA and NAcc (68).
Acute THC also increases the reinforcing efficacy of intravenously
administered heroin (69) facilitates the release of DA from NAc
DAergic terminals (70, 71) and directly activates VTA DA neu-
rons recorded in vivo (72). In rat neurodevelopmental models,
adolescent THC exposure has been reported to strongly increase
opiate self-administration in early adulthood (73) and potenti-
ate mesolimbic DA release (74). Functionally, this effect has been
linked to THC-induced up-regulation of the pro-enkephalin pep-
tide, directly in the shell region of the nucleus accumbens [NAc;
(75)]. Such findings following adolescent THC exposure, simi-
lar to those reported with schizophrenia-related emotional and
behavioral abnormalities, further implicate the importance of
THC exposure during particular neurodevelopmental windows,
which in turn influence later adulthood phenotypes. Neverthe-
less, beyond the actions of CB1 transmission on DAergic signaling
within the mesolimbic system, it is currently not understood how
CB1 transmission modulates reward processing via interactions
with regions extrinsic to the mesolimbic system, such as the PFC
and BLA, nor how such systems level interactions may control sen-
sitivity to the rewarding and dependence-producing properties of
opiate-class drugs of abuse.
CANNABINOID MODULATION OF MESOCORTICOLIMBIC
ACTIVITY: IMPLICATIONS FOR REWARD PROCESSING
DYSREGULATION IN PSYCHIATRIC DISORDERS
Beyond the VTA and NAc, prefrontal cortical regions are involved
importantly in the modulation of opiate reward salience. Specifi-
cally, the PLC division of the mammalian PFC has been demon-
strated to provide modulation of morphine-related reward pro-
cessing and neuronal populations within the PLC are critically
involved in the acquisition, expression, and extinction of opiate-
related reward learning and memory (48, 76, 77). For exam-
ple, using in vivo multi-unit recordings in behaving rats, we
have demonstrated previously that sub-populations of neurons
within the PLC actively encode associative memories related to
the rewarding effects of morphine, as measured in the conditioned
place preference (CPP) procedure, a Pavlovian conditioning model
of drug seeking behaviors (76). Similar to the role of PFC neurons
in the encoding of aversive, fear-related information, the neuronal
encoding of reward-related information in the PLC is controlled
by functional input from the BLA (49). Given these dual roles for
PLC neuronal sub-populations in the processing of both aversive,
fear-related information (34, 36, 38) and rewarding, appetitive
opiate-related learning and memory (48, 76), we examined how
direct modulation of CB1 receptor signaling within the PLC may
modulate the processing of opiate-related reward information,and
how CB1 transmission directly within the mammalian PLC may
modulate opiate reward transmission via outputs to the VTA and
mesolimbic system (78).
Using an unbiased CPP procedure in rats, we performed
bilateral microinfusions of either a direct CB1 receptor agonist
(WIN 55, 212-2) or antagonist (AM 251), prior to behavioral
conditioning sessions using either a highly rewarding, supra-
threshold conditioning dose of morphine (5 mg/kg; i.p.) or
a sub-threshold, non-rewarding conditioning dose of systemic
morphine (0.05 mg/kg), based upon previously established and
reported behavioral dose-response curves for morphine (47, 48).
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Surprisingly, we found that blockade of CB1 transmission directly
within the PLC division of the PFC, strongly potentiated the
reward salience of normally sub-reward threshold conditioning
effects of morphine while having no effects on the rewarding
behavioral properties of normally supra-threshold, highly reward-
ing doses of morphine. These results indicated that rather than
blunting the motivational salience of morphine, blockade of CB1
transmission directly in the PLC was able to potentiate the reward
salience of sub-threshold reward signals. In stark contrast, direct
activation of CB1 receptors within the PLC produced the opposite
pattern of behavioral results; switching the motivational valence
of a normally highly appetitive conditioning dose of systemic
morphine from rewarding, to aversion, with rats demonstrat-
ing strong conditioned place aversions (CPA) to environments
paired previously with supra-threshold doses of morphine (78).
Given previous reports that direct activation of CB1 transmis-
sion in the PFC or BLA is able to strongly potentiate the aversive
salience of normally non-salient conditioning levels of foot-shock
(9, 38) while blocking CB1 transmission is capable of blocking
the acquisition of salient associative fear memories, these results
are seemingly incongruent with a role for hyperactive intra-PFC
CB1 receptor substrates as an amplification mechanism for emo-
tionally salient information. Furthermore, these opposite effects
of intra-PFC CB1 receptor activation vs. blockade on processing
of reward-related associative memory may suggest that the func-
tional role of intra-PLC CB1 receptor transmission, is capable
of producing bi-directional modulation of aversive or reward-
ing emotional information in opposite directions, depending on
the motivational valence of the conditioning events (e.g., fear vs.
reward based learning assays). However, an alternative explana-
tion is that hyper-activation or CB1 receptor transmission within
the PFC may amplify specifically negative aspects of associative
learning stimuli. In this case, sub-threshold fear-inducing stimuli
would be behaviorally potentiated in the fear learning paradigm,
while the aversive stimulus properties of morphine would similarly
be amplified and expressed as CPA, as measured in place condi-
tioning procedures (78). Indeed, as will be discussed presently,
morphine possesses powerful aversive stimulus effects, in addi-
tion to its potent rewarding properties (79, 80). Thus, intra-PFC
CB1 receptor hyper-stimulation can amplify aversive emotional
information whilst concomitantly switching reward signals into
aversion. In contrast, hypoactive states of intra-PFC CB1 activ-
ity can blunt the salience of normally aversive emotional events,
while concomitantly potentiating the reward salience of nor-
mally sub-reward threshold stimuli. Interestingly, both effects
are mediated through DA-dependent transmission as systemic
blockade of both DA D1 and D2 transmission with a broad-
spectrum DA receptor antagonist was sufficient to block both
the reward potentiating effects of intra-PLC receptor blockade,
and the aversion-inducing properties of intra-PLC CB1 receptor
activation, suggesting that the final common output for intra-
PFC mediated modulation of opiate-related reward signaling is
through a DAergic mechanism.
As with many drugs of abuse, opioid compounds, including
morphine, possess both rewarding and aversive stimulus proper-
ties that can be demonstrated in a variety of behavioral assays
(47, 67, 79–81). Following the demonstration that intra-PLC CB1
receptor modulation could switch the motivational valence of
opiates from reward to aversion or potentiate the motivational
salience of normally sub-reward threshold doses of morphine,
we examined which specific opiate-receptor substrates within the
VTA may mediate these effects. Several pieces of evidence demon-
strate that the rewarding or aversive stimulus properties of opiates
can be dissociated via separate µ-opiate-receptor (MOR) vs. κ-
opiate-receptor (KOR) substrates within the VTA. For example,
while transmission via MOR receptors is associated with indirect
activation of DA neurons (82, 83), activation of KOR substrates
in the VTA is linked to aversive opiate effects (80) and to the
inhibition of VTA DAergic neuronal populations (84, 85). Given
these dissociable neuronal and behavioral effects of MOR vs. KOR
receptor populations, we hypothesized that the ability of intra-PLC
CB1 receptor blockade or activation to modulate opiate-related
motivational signals may depend upon signaling through these
separate receptor substrates directly in the VTA. Consistent with
this hypothesis, we found that the ability of intra-PLC CB1 recep-
tor activation to switch a normally rewarding dose of morphine
into an aversive behavioral effect was dependent on a KOR sig-
naling mechanism directly in the VTA. In contrast, the ability
of intra-PLC CB1 receptor blockade to potentiate the reward-
ing salience of normally sub-reward threshold conditioning doses
of morphine was mediated through a MOR-dependent mecha-
nism, directly in the VTA. Currently, the precise mechanisms by
which intra-PFC CB1 activation or blockade may differentially
activate either a MOR-dependent opiate reward system vs. a KOR-
dependent aversion signaling pathway are not known. However,
given that both behavioral phenomena are dependent upon DAer-
gic signaling (78), it is likely that there is a convergence of these
motivational effects via DA receptor substrates emerging from
the VTA. One possibility comes from anatomical evidence from
Ford (86), who reported that VTA KOR-associated DA neuron
sub-populations preferentially projected to NAc targets whereas
VTA MOR-associated sub-populations showed preferential tar-
geting to the BLA. Interestingly, the NAc has been implicated
in mediating DA-dependent aversive motivational effects, such
as those associated with nicotine (87, 88). Furthermore, intra-
BLA DA receptor transmission has been demonstrated to strongly
modulate the rewarding properties of opiates (47, 89). In this
case, the aversive or rewarding properties associated with opiate
conditioning could be mediated through DA receptor-dependent
substrates, but via anatomically distinct projections. Future studies
are required to more precisely determine the functional rela-
tionships between these VTA output target pathways and how
bi-directional CB1 signaling within the PFC may differentially
trigger these systems via descending influences on VTA MOR
vs. KOR signaling substrates. Thus, via direct interactions with
sub-cortical DAergic motivational systems within the VTA, corti-
cal CB1 receptors are capable of modulating reward processing,
and even switching the emotional valences of normally highly
rewarding conditioning stimuli, such as morphine, into aversive
behavioral effects (78).
Beyond the modulation of opiate-receptor-mediated motiva-
tional effects, a recent study from Katsidoni et al. (90) reported
that administration of THC was capable of bi-phasically modu-
lating reward processing and behavioral activation as measured in
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a rewarding electrical brain stimulation paradigm involving self-
stimulation of the medial forebrain bundle. While lower THC
doses were shown to enhance generalized reward processing,
higher doses caused blunted reward activity. Furthermore, beyond
the opiate-receptor system, a large body of research implicates a
role for CB1 transmission in the modulation of non-drug, natural
reward stimuli such as food reinforcers. For example, Hernandez
and Cheer (91) reported that blockade of CB1 transmission could
blunt the rewarding properties of natural food reinforcers and
concomitantly block neuronal reward-related signaling in neurons
recorded from the NAc. Together, such evidence demonstrates
a more generalized role for CB1 receptor-mediated modulation
of reward information within the mesocorticolimbic system that
can transcend drug-related motivational processing. Future stud-
ies will likely reveal more specific mechanisms related to different
classes of rewarding stimulation and how CB1-mediated trans-
mission may differentially influence separate classes of behavioral
reinforcers.
While further studies are required to precisely identify how
intra-PLC CB1 receptor signaling may directly modulate VTA
DAergic neuronal responses via KOR vs. MOR-dependent sig-
naling mechanisms, a previous report has demonstrated that
MOR-associated VTA DAergic populations preferentially project
to the BLA, while KOR-associated DAergic neurons show more
specific projections to NAc targets (86). Thus,one possibility is that
intra-PLC CB1 transmission may serve to shunt intra-VTA reward
vs. aversion transmission through distinct efferent pathways from
the VTA; a VTA→NAc, KOR aversion pathway, vs. a VTA→BLA,
MOR-dependent reward. Such a model would be consistent with
previous findings demonstrating that DAergic signaling within
the NAc is involved importantly in mediating motivationally aver-
sive behaviors, such as those associated with nicotine (88, 92),
and findings demonstrating that DAergic transmission within the
BLA is responsible for modulating opiate-related reward salience
(47, 89, 93). Furthermore, these findings (78) are consistent with
previous reports demonstrating that genetic deletion of the CB1
receptor renders mutant mice unresponsive to the rewarding and
dependence-producing properties of opiates (65). Interestingly,
systemic administration of CB1 antagonists has been reported
to increase expression levels of spinal KOR substrates, and a
resulting potentiation in KOR-mediated analgesic responses (94).
While these studies used non-localized administration or analy-
ses of MOR or KOR-mediated responses following systemic CB1
receptor manipulations, they further point to functionally conver-
gent pathways mediating CB1 and opiate-receptor-specific moti-
vational and behavioral phenomena. Importantly, the ability of
cortical CB1 signaling to modulate reward processing by acting on
specific opiate-receptor substrates localized to sub-cortical reward
FIGURE 3 | Schematic summary of the effects of hyperactive vs.
hypoactive CB1 receptor states in the mammalian PFC. While a state of
CB1 hyperactivity is linked to an amplification in emotional salience,
particularly in terms of increased sensitivity to fear-related stimuli in rats
and increased paranoid psychosis in human subjects. CB1 receptor
overstimulation also switches normally rewarding stimuli into aversive
effects, mediated through down-stream signaling of KOR receptor
substrates in the VTA. In contrast, a state of CB1 hypoactivity is linked to
the blunting of emotional salience, a blockade of fear-related memory
formation. In contrast, CB1 receptor blockade potentiates the reward
salience of opiate-related cues, via the activation of a MOR receptor
substrate in the VTA.
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circuits, may point to another common point of convergence
resulting from aberrant ECB transmission in the cortex, linking
these abnormalities not only to disturbances in aversive emo-
tional information processing, but to abnormal reward-related
learning and memory, commonly seen in schizophrenia patient
populations (15, 95).
SUMMARY AND FUTURE DIRECTIONS
As reviewed above, a diverse and convergent body of evidence now
suggests that disturbances in ECB signaling within mesocorticol-
imbic circuitry may underlie sub-cortical DAergic dysregulation
linked to a variety of neuropsychiatric disorders such as addiction
and schizophrenia. Specifically within PFC circuits, CB1 recep-
tor transmission appears to control bi-directional modulation of
emotional salience, both in the context of aversive, negative events,
and rewarding, appetitive motivational stimuli (Figure 3). The
underlying mechanisms controlling these bi-directional effects of
cortical ECB signaling are only now beginning to be elucidated.
As the evidence presented above highlights, schizophrenia-related
psychopathology likely involves core deficits in emotional pro-
cessing and memory formation related to both aversive, negative
stimuli and in terms of aberrant reward processing, indicated by
high rates of substance abuse co-morbidities in these patient popu-
lations. Nevertheless, many critical questions remain. For example,
does cortical hyperactivity of CB1 receptor substrates amplify the
aversive emotional salience of normally non-salient fear stimuli
via interactions with DAergic substrates in the mesocorticolimbic
pathway and might these mechanisms share common interac-
tions with opiate-receptor motivational signaling pathways in the
mesolimbic circuitry?
In addition, some intriguing comparisons between the pro-
psychotic, acute effects of cannabis vs. the longer term effects
of cannabis has shown interesting differences in terms of their
presumed effects on DAergic transmission. For example, as previ-
ously discussed, post-mortem analyses of brain tissue from human
schizophrenia patients has demonstrated profound increases in
CB1 receptor binding; an effect specifically evident in paranoid
schizophrenia sub-groups (25, 96). In contrast, recent clinical
findings have demonstrated significantly diminished DA synthe-
sis capacity in regular marijuana users compared with non-users
(97) and evidence of attenuated DA receptor expression lev-
els in current or recently abstinent marijuana users (98, 99).
However, hypo-DAergic effects of cannabis use would seem func-
tionally contradictory to prior evidence suggesting pro-psychotic
effects of cannabis exposure, effects that are generally posited to
hyper-DAergic states. Furthermore, hypo-DAergic states would
seem incongruent with reports demonstrating increased sensitiv-
ity to the addictive properties of opiates, particularly following
chronic adolescent THC exposure (73, 75). While further studies
are required to more fully address and corroborate these mecha-
nisms, it is likely that increasing evidence will point to dysregula-
tion in cortical ECB signaling substrates and their down-stream
functional interactions with mesocorticolimbic circuits as crit-
ical underlying variables related to a variety of neuropsychiatric
conditions, including schizophrenia-related psychoses, addictions,
and their associated emotional processing, learning, and memory
deficits.
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